Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.

Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling. The Jak kinases exhibit distinct cytokine receptor association profiles and so transduce different signals. Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors containing the common gamma-chain, gammac. Patients unable to signal via gammac present with severe combined immunodeficiency (SCID). The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants. Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941. The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated. The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop. Such a direct coupling has not been previously observed in tyrosine kinases and may be unique to Jak kinases. The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.

[1]  S V Evans,et al.  SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. , 1993, Journal of molecular graphics.

[2]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[3]  Eugene C. Petrella,et al.  The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine , 2004, Journal of Biological Chemistry.

[4]  L. Toledo,et al.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.

[5]  A. Verma,et al.  Jak family of kinases in cancer , 2003, Cancer and Metastasis Reviews.

[6]  K Imada,et al.  The Jak-STAT pathway. , 2000, Molecular immunology.

[7]  S. Rane,et al.  JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. , 1994, Oncogene.

[8]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[9]  B. Mroczkowski,et al.  Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. , 1999, Structure.

[10]  Stevan R. Hubbard,et al.  Structure and autoregulation of the insulin-like growth factor 1 receptor kinase , 2001, Nature Structural Biology.

[11]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[12]  A. Papageorgiou,et al.  Is JAK3 a new drug target for immunomodulation-based therapies? , 2004, Trends in pharmacological sciences.

[13]  M. Säemann,et al.  Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor , 2004, European Surgery.

[14]  L. Notarangelo,et al.  Eleven novel JAK3 mutations in patients with severe combined immunodeficiency—including the first patients with mutations in the kinase domain , 2001, Human mutation.

[15]  J. O’Shea,et al.  Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Rothman,et al.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. , 1997, Journal of immunology.

[17]  V S Lamzin,et al.  Automated refinement for protein crystallography. , 1997, Methods in enzymology.

[18]  Takamune Takahashi,et al.  Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases , 1994, FEBS letters.

[19]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[20]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[21]  Á. Carracedo,et al.  Mutation analysis of the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer , 2001, Human mutation.

[22]  S. Hubbard Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[23]  M. Vihinen,et al.  Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency , 2001, Human mutation.

[24]  C. Sawyers,et al.  Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.

[25]  J. Johnston,et al.  Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Rane,et al.  Janus kinases: components of multiple signaling pathways , 2000, Oncogene.

[27]  R Berger,et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.

[28]  O. Silvennoinen,et al.  Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.

[29]  R J Read,et al.  Pushing the boundaries of molecular replacement with maximum likelihood. , 2003, Acta crystallographica. Section D, Biological crystallography.

[30]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[31]  J. O’Shea,et al.  Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. , 2004, Blood.

[32]  J. Zheng,et al.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[33]  J. Puck,et al.  Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. , 1997, The Journal of pediatrics.

[34]  K. K. Jacob,et al.  Insulin receptor tyrosine kinase activity and phosphorylation of tyrosines 1162 and 1163 are required for insulin-increased prolactin gene expression , 2002, Molecular and Cellular Endocrinology.

[35]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[36]  L. Lally The CCP 4 Suite — Computer programs for protein crystallography , 1998 .

[37]  N. Danial,et al.  Jak-STAT signaling induced by the v-abl oncogene. , 1995, Science.

[38]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[39]  J. O’Shea,et al.  Jak3 and the pathogenesis of severe combined immunodeficiency. , 2004, Molecular immunology.